Matthew S. Sulkin1, PhD; Zachary C. Berwick1, PhD; James B. Hermiller2, MD; Jose A. Navia3, MD; Ghassan S. Kassab4*, PhD
1. 3DT Holdings LLC, San Diego, CA, USA; 2. St. Vincent Hospital and The Care Group, Indianapolis, IN, USA; 3. Department of Surgery, Austral University, Buenos Aires, Argentina; 4. California Medical Innovations Institute, San Diego, CA, USA
Aims: Percutaneous structural heart therapies, such as mitral value repair, require site-specific transseptal access (TSA). This can be challenging for interventional cardiologists. We de
